TY - JOUR
T1 - Extraskeletal osteosarcoma an international rare cancer network study
AU - Sio, Terence T.
AU - Vu, Charles C.
AU - Sohawon, Schoeb
AU - Houtte, Paul Van
AU - Thariat, Juliette
AU - Novotny, Paul J.
AU - Miller, Robert C.
AU - Bar-Sela, Gil
N1 - Publisher Copyright:
© 2013 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016
Y1 - 2016
N2 - Objectives: To report characteristics, treatment, and outcomes for an international cohort of patients with extraskeletal osteosarcoma (ESOS). Materials and Methods: Through the Rare Cancer Network, retrospective data on patients with ESOS were collected. Patient characteristics, multimodality treatment information, and survival status were analyzed. Results: Thirty-seven patients in 4 health care institutions were identified. Thirty-one (86%) patients had grade 3 or 4 tumors. Most patients (27 [73%]) had stage III disease. Fourteen (38%) received neoadjuvant chemotherapy or chemoradiation. Of 28 (85%) who underwent surgery, 21 (75%) had free margins achieved and 15 (41%) subsequently received adjuvant chemotherapy. At median follow-up of 45 months, 20 (55%) patients were alive, 13 (43%) of whom were disease free. Univariate analysis showed that poor overall survival was related to stage IV (P < 0.001), no surgery (P < 0.001), primary size >10 cm (P = 0.002), and age (P = 0.002). In multivariate analysis, primary size >10 cm (P = 0.005) was prognostic for overall survival. For patients without metastases, univariate analysis showed disease-free survival (DFS) related to primary size >10 cm (P = 0.003), surgery (P = 0.004), local recurrence (P = 0.003), and age (P < 0.001). In multivariate analysis for DFS, primary size >10 cm (P = 0.01) and older age (P < 0.001) were significant for worse outcome. Conclusions: Multimodality treatment remains standard for localized ESOS, with indications for neoadjuvant therapy less clear. Larger tumor size and older age were prognostic of poorer DFS.
AB - Objectives: To report characteristics, treatment, and outcomes for an international cohort of patients with extraskeletal osteosarcoma (ESOS). Materials and Methods: Through the Rare Cancer Network, retrospective data on patients with ESOS were collected. Patient characteristics, multimodality treatment information, and survival status were analyzed. Results: Thirty-seven patients in 4 health care institutions were identified. Thirty-one (86%) patients had grade 3 or 4 tumors. Most patients (27 [73%]) had stage III disease. Fourteen (38%) received neoadjuvant chemotherapy or chemoradiation. Of 28 (85%) who underwent surgery, 21 (75%) had free margins achieved and 15 (41%) subsequently received adjuvant chemotherapy. At median follow-up of 45 months, 20 (55%) patients were alive, 13 (43%) of whom were disease free. Univariate analysis showed that poor overall survival was related to stage IV (P < 0.001), no surgery (P < 0.001), primary size >10 cm (P = 0.002), and age (P = 0.002). In multivariate analysis, primary size >10 cm (P = 0.005) was prognostic for overall survival. For patients without metastases, univariate analysis showed disease-free survival (DFS) related to primary size >10 cm (P = 0.003), surgery (P = 0.004), local recurrence (P = 0.003), and age (P < 0.001). In multivariate analysis for DFS, primary size >10 cm (P = 0.01) and older age (P < 0.001) were significant for worse outcome. Conclusions: Multimodality treatment remains standard for localized ESOS, with indications for neoadjuvant therapy less clear. Larger tumor size and older age were prognostic of poorer DFS.
KW - Extraskeletal osteosarcoma
KW - Multimodality therapy
KW - Outcome
KW - Rare Cancer Network
KW - Soft-tissue sarcoma
UR - http://www.scopus.com/inward/record.url?scp=84957841842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957841842&partnerID=8YFLogxK
U2 - 10.1097/COC.0000000000000005
DO - 10.1097/COC.0000000000000005
M3 - Article
C2 - 24401667
AN - SCOPUS:84957841842
SN - 0277-3732
VL - 39
SP - 32
EP - 36
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 1
ER -